ViaDerma, Inc. Looks to have Sales Representatives Selling its FDA Registered Medication VitaStem to a Network of 1000 Physician Offices Nationwide in 2018

LOS ANGELES, CA–(Marketwired – December 07, 2017) – ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has begun sales and distribution of its highly anticipated topical antibiotic ointment Vitastem. ViaDerma will work with a new sales and marketing group to put 25 sales representatives on the ground selling ViaDerma’s products to networks of Hospitals and directly to physicians’ offices. The projected revenues for 2018 from this initiative should generate $6.9 million dollars.

The Company has a new distributor in the Philippines, whereby ViaDerma and Biogenx have agreed in principle to terms to distribute VitaStem in the Philippines. The Agreement calls for purchase minimums of 42,500 units the first year, 75,000 the 2nd year, and 125,000 units the 3rd year. The Company expects to ramp up production, monthly as interest in the product continues to grow. ViaDerma estimates they could ramp up production to 75,000 units per month over the next few years.

ViaDerma also believes sales in Japan will start soon with an initial demand for approximately 10,000 units of VitaStem per month. Conservatively the Company is projecting initial revenues from Japan of over $2 million dollars per year for 2018. ViaDerma President, D. Christopher Otiko will travel to Japan in January 2018 to meet with distributors and physicians who will be dispensing Vitastem to their patients.

Its marketing, sales and distribution partner, Biogenx, Inc. has been preselling the product, under the name of VitaStemtm. Which now retails for $79 and can be purchased online at The Company plans to start manufacturing the second production run of the product and now has streamlined the manufacturing.

The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for “Aqueous Topical Applications” for human and veterinary uses. The Company would combine its proprietary solutions with CBD’s and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) “Intellectual Property Portfolio” in 2018.

ViaDerma President, Dr. Christopher Otiko, said, “Now that we have the manufacturing capabilities we are concentrating on ramping up sales and distribution and are seeing the orders come in from several countries. The response from our customers in all our testing trials have shown positive results and overwhelming interest in our products around the world. Our contract manufacturer has now streamlined the process and has the capabilities to manufacture most of our products. We are now manufacturing our new products and look forward to delivering several high-quality pharmaceuticals to our distributors.”

About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma’s products use an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD’s and THC with the delivery system was filed in 2017. The use of CBD’s is for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Crohn’s disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit:

Forward Looking Statements
Forward-Looking Statements certain statements in this release that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as “anticipate,” “believe,” “expect,” “future,” “may,” “will,” “would,” “should,” “plan,” “projected,” “intend,” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company’s future operating results are dependent upon many factors, including but not limited to the Company’s ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company’s control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.

Contact information:
Investor Relations
Phone: 310-734-6111